Document is current

Any future updates will be listed below

ASO Author Reflections: Translating Trial Evidence into Real-World Benefit: First-Line Pembrolizumab in Advanced NSCLC

Crossref DOI link: https://doi.org/10.1245/s10434-026-19308-7

Published Online: 2026-02-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark